Moderna's patent lawsuit claiming Pfizer and BioNTech copied its COVID-19 vaccine technology will be put on hold while the U.S. Patent Office determines whether two of the three Moderna patents at issue are valid.
Millions in Sackler donations sat dormant, rising in value as the opioid epidemic raged and as other institutions distanced themselves from the makers of a notorious painkiller.
Trikafta, which was approved in 2019 and works for about 90% of patients with the deadly genetic disease, had an annual list price of more than $326,000 in the United States at the end of last year.
In the first three months of the year, there were 323 active medication shortages, surpassing the previous high of 320 shortages in 2014. It also amounts to the most shortages since a pharmacists' trade group started keeping track in 2001.
Medicare's actuaries expect the drug Leqembi to cost the traditional Medicare program around $550 million in 2024 and the entire Medicare program $3.5 billion in 2025.